HOW WE WORK
For Healthcare Companies
We work with 3-5 medical technology companies at a time. These are late-stage startups with breakthrough solutions that have moved past the science risk.
What We Look For:
• Proven technology platform with clinical or real-world validation
• Strong management team with relevant experience
• Secured intellectual property (issued patents or strong applications)
• Clear regulatory pathway to approval
• Significant market opportunity
• Technologies that improve patient outcomes
Retainer Structure:
Retainer paid on the first of each month. This accumulates as a credit applied at closing. If you cancel the agreement, retainers already paid are non-refundable.
Success Fee:
2.5% cash payment and 2.5% equity ownership of the capital raised.
For Institutional Investors
We provide access to pre-vetted late-stage healthcare opportunities.
Every company has completed rigorous due diligence addressing:
• Scientific and technical validation
• Regulatory pathway assessment
• Intellectual property strength
• Commercial viability and market opportunity
• Management team capabilities
• Financial sustainability
You receive detailed investment memoranda for each opportunity. We facilitate direct introductions to management teams for qualified investors.
Our investor network includes venture capital firms with late-stage biotech funds, family offices focused on healthcare innovation, and institutional investors seeking FDA-stage companies.
Our process
1. Initial Meeting
3. Positioning and Introductions
2. Comprehensive Due Diligence
We meet in person to discuss your technology, regulatory pathway, capital requirements, and commercialization plan. This conversation determines if we're the right fit.
2. Comprehensive Due Diligence
3. Positioning and Introductions
2. Comprehensive Due Diligence
If we decide to partner, we conduct thorough review of your IP, clinical data, regulatory strategy, management team, and financial projections. This takes 4-6 weeks.
3. Positioning and Introductions
3. Positioning and Introductions
3. Positioning and Introductions
We develop your investment materials and facilitate introductions to institutional investors and family offices in our network.
4. Ongoing Support
3. Positioning and Introductions
3. Positioning and Introductions
Following successful capital raise, we provide strategic guidance on regulatory submissions, clinical trials, and commercial launch. Our equity position ensures we're incentivized for your long-term success.
Background
Benoît Lapointe, Principal
Ben spent years as an investment advisor at RBC Dominion Securities in Toronto, working with high-net-worth clients on complex transactions. For the past 20 years, he's advised on healthcare innovation and commercial real estate, which provides perspective on both technology validation and capital deployment.